RAD — Radiopharm Theranostics Share Price
Last trade - 00:00- AU$17.47m
- AU$15.68m
- AU$0.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.49% | ||
| Return on Equity | -108.75% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | n/a | 0.29 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company. The Company is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The Company has a pipeline of six platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including breast, kidney and brain. The Company's technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labeled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 11th, 2021
- Public Since
- November 25th, 2021
- No. of Shareholders
- 1,998
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 371,639,096
- Address
- 62 Lygon Street, Carlton, Level 3, MELBOURNE, 3053
- Web
- https://radiopharmtheranostics.com/
- Phone
- +61 398245254
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for RAD
Similar to RAD
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:17 UTC, shares in Radiopharm Theranostics are trading at AU$0.05. This share price information is delayed by 15 minutes.
Shares in Radiopharm Theranostics last closed at AU$0.05 and the price had moved by -67.59% over the past 365 days. In terms of relative price strength the Radiopharm Theranostics share price has underperformed the ASX All Ordinaries Index by -69.81% over the past year.
The overall consensus recommendation for Radiopharm Theranostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Radiopharm Theranostics does not currently pay a dividend.
Radiopharm Theranostics does not currently pay a dividend.
Radiopharm Theranostics does not currently pay a dividend.
To buy shares in Radiopharm Theranostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.05, shares in Radiopharm Theranostics had a market capitalisation of AU$17.47m.
Here are the trading details for Radiopharm Theranostics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RAD
Based on an overall assessment of its quality, value and momentum Radiopharm Theranostics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Radiopharm Theranostics is AU$0.70. That is 1397.87% above the last closing price of AU$0.05.
Analysts covering Radiopharm Theranostics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.08 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Radiopharm Theranostics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -68.89%.
As of the last closing price of AU$0.05, shares in Radiopharm Theranostics were trading -45.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Radiopharm Theranostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Radiopharm Theranostics' directors